ARTICLE | Product Development
c-Met's highs and lows
What may explain divergent data for c-Met cancer blockers from Aveo, Genentech
May 28, 2012 7:00 AM UTC
Differences in the manner of c-Met inhibition and EGFR mutation status may help explain apparently contradictory biomarker results in non-small cell lung cancer reported for two anti-c-Met mAbs, one from Aveo Pharmaceuticals Inc. and the other from Genentech Inc.
Activation of c-Met is thought to trigger tumor cell survival, growth and metastasis in a variety of tumor types...